Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis

Leukemia

Volumn 11, Issue 9, 1997, Pages 1523-1532

  Bailly, J D ^a   Skladanowski, A ^b   Bettaieb, A ^a   Mansat, V ^a   Larsen, A K ^b   Laurent, G ^a,c  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CHU PURPAN   (France)

Author keywords

Apoptosis; Chemoresistance; Leukemia; Mitoxantrone

Indexed keywords

DNA FRAGMENT; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOXANTRONE; TRANSCRIPTION FACTOR AP 1;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; DNA PROTEIN COMPLEX; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MITOSIS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030846601     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400762     Document Type: Article

References (13)

1. McCulloch EA. Regulatory mechanisms affecting the blast stem cell of acute myeloblastic leukemia. J Cell Physiol 1986; 4: 27-33.
2. Metcalf D. The roles of stem cell self-renewal and autocrine growth factor production in the biology of myeloid leukemia. Cancer Res 1989; 49: 2305-2311.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes B, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
4. Ross DD. Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia. Curr Opin Oncol 1991; 3: 21-29.
5. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
6. List AF, Spier CM, Cline A, Dol DC, Garewal H, Morgan R, Sandberg AA. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasias is associated with a stem cell phenotype. Br J Haematol 1991; 78: 28-34.
7. + acute myeloid leukemia cell. Blood 1993; 82: 3157-3162.
8. Bailly JD, Muller C, Jaffrézou JP, Demur C, Cassar G, Bordier C, Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cells. Leukemia 1995; 9: 799-807.
9. Hill B, Hosking LK, Shellard S, Whelan DH. Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro. Cancer Chemother Pharmacol 1989; 23: 140-144.
10. Shenkenberg TD, Von Hoff D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67-81.
11. Arlin ZA, Case DC, Moore J. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphoblastic leukemia (ANLL). Leukemia 1990; 4: 177-183.
12. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002-2009.
13. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993; 82: 3133-3140.